ZGNX News and Press, Zogenix Inc. From 09/30/20

Thesis that FDA approval of Fintepla would immediately unlock value was wrong. With ZGNX down nearly 40% since, and the story still fully intact, the stock is now highly attractive. The recent $200M convertible debt deal surprised many. This large capital raise, on top of the $399...

YouTuber Boston Biotech Investor posted this review of Zogenix on his YouTube channel today. The stock has been hit due to dilution as a result of the $200M convertible debt offering it price yesterday, as we reported. Here's Boston Biotech Investor's analysis: For further details see: ...

Zogenix (ZGNX) prices $200M 2.75% convertible senior notes due 2027 in a private offering to institutional buyers.Initial purchasers has an option an additional  $30M From and after July 1, 2027, noteholders may convert their notes at any time at their election until the close of bu...

EMERYVILLE, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX) today announced the pricing of its offering of $200,000,000 aggregate principal amount of 2.75% convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional ...

Gainers: [[NKE]] +10.9%. [[BZH]] +7.3%. [[AROC]] +7.3%. [[EQX]] +6.4%. [[RPAI]] +5.0%.Losers: [[WVE]] -24.2%. [[SFIX]] -16.7%. [[ACB]] -15.4%. [[ZGNX]] -8.3%. [[SCS]] -7.2%. For further details see: NKE, EQX, SFIX and ZGNX among after-hours movers

Zogenix ([[ZGNX]] -1.1%) plans to offer $200M principal amount of convertible senior notes due 2027 in a private offering to institutional buyers.Interest rate, initial conversion rate to be determined at pricing. Initial purchasers' additional option is $30M of notes.The company intends...

EMERYVILLE, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX) today announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offe...

Correction: In this updated news release issued September 21, 2020 by Zogenix, Inc, the name of the organization, WorldWideWomen, has been corrected. The full corrected press release follows. EMERYVILLE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global bio...

EMERYVILLE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced the appointments of Caroline M. Loewy, Mary E. Stutts and Denelle J. Waynick to newly created seats on its...

Ligand inks deal to acquire Taurus and xCella Biosciences Ligand Pharmaceuticals Inc. ( LGND ) reported that it has inked a deal to acquire two companies, xCella Biosciences Inc. and Taurus Biosciences. Both these companies are privately held and are expected to boost Ligand’s Omn...